FATE News and Press, Fate Therapeutics Inc. From 05/12/20

Fate Therapeutics, Inc. (FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Ted Tenthoff - Piper Sandl...

Fate Therapeutics (NASDAQ: FATE ): Q1 GAAP EPS of -$0.44 misses by $0.05 . More news on: Fate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy Engineered with Three Active Anti-tumor Modalities Second FT596 IND Allowed by FDA for Relapse Prev...

SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the retirement of Amir Nashat, Sc.D., Managing ...

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call an...

The therapeutic qualities of living cells have tremendous potential to improve patient outcomes for a broad range of ailments, from cancers to autoimmune diseases. Engineering cell therapies isn't easy, and there's much left to understand and quantify when it comes to the complexity of biology, ...

Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive Lice...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

Introduction Since I first wrote about Atara Biotherapeutics ( ATRA ) in October 2019, its share price has gone through a rollercoaster ride, reflecting the binary nature of investing in clinical-stage biotech companies. Share prices went as high up to over $17, before dropping by over 50%...

Shares of Fate Therapeutics (NASDAQ: FATE) dropped nearly 24% last month, according to data provided by S&P Global Market Intelligence . That was almost twice the fall of the S&P 500 , which declined 12.5% in March due to the abrupt uncertainty ushered in by the coronavirus pandemi...